You are here

  • Home
  • Archive
  • Volume 8, Issue Suppl 3
  • 318 Olaparib plus pembrolizumab in patients with previously treated advanced solid tumors with homologous recombination repair mutation and/or homologous recombination repair deficiency: KEYLYNK-007

Article metrics

Article menu

Download PDFPDF

Regular and young investigator award abstracts
Clinical trials in progress
318 Olaparib plus pembrolizumab in patients with previously treated advanced solid tumors with homologous recombination repair mutation and/or homologous recombination repair deficiency: KEYLYNK-007

 

Online download statistics by month:

Online download statistics by month: November 2020 to June 2025

AbstractFullPdf
Nov 2020207021
Dec 20202603
Jan 20212705
Feb 20213508
Mar 20215206
Apr 20215605
May 2021805
Jun 20210011
Jul 2021006
Aug 2021007
Sep 2021004
Oct 202146029
Nov 202152013
Dec 20214801
Jan 20227605
Feb 20223106
Mar 20226207
Apr 20229806
May 20226305
Jun 20227609
Jul 20228107
Aug 2022101015
Sep 20228106
Oct 202265010
Nov 202287012
Dec 20227002
Jan 202386013
Feb 202372012
Mar 2023116016
Apr 202356010
May 20239603
Jun 20236405
Jul 20238808
Aug 20236005
Sep 202366026
Oct 20238605
Nov 202312207
Dec 20236806
Jan 2024401
Feb 20245002
Mar 202480011
Apr 20244008
May 20243605
Jun 20247401
Jul 20247601
Aug 20244005
Sep 20245805
Oct 20243401
Nov 202456015
Dec 20243604
Jan 20254205
Feb 2025402
Mar 2025007
Apr 20250020
May 2025009
Jun 2025004
Total30580436